Video: Update on Progress with Proprietary LB-100 Compound
March 20, 2024
Article: Too much of a good thing in Nature Reviews Cancer
April 30, 2024
First in Human Episode #59 featuring Bas van der Baan
Join as we dive deep into the world of oncology drug development with Bas van der Baan of Lixte. Discover the inspiration behind Lixte’s focus on PP2A inhibitors and how this innovative approach is poised to revolutionize cancer treatment by enhancing chemotherapy and immunotherapy responses. Bas shares insights into ongoing clinical trials, regulatory considerations, and Lixte’s ambitious long-term goals in expanding their impact on cancer care. Tune in to explore the cutting-edge science and vision driving Lixte’s journey in the fight against cancer.